Literature DB >> 23438977

Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor.

Xuan Zou1, Fangtian Dong, Shuying Zhang, Rong Tian, Ruifang Sui.   

Abstract

The familial transthyretin (TTR) amyloidosis (FTA) demonstrates variable penetrance of clinical features associated with mutations in the plasma thyroid hormone-binding protein TTR gene. The purpose of this study was to assess the ocular features, to analyze vitreous and serum vascular endothelial growth factor (VEGF) levels, and to identify the genetic defect in a Chinese family with TTR FTA. The pedigree of interest was a three-generation family with eleven members. The primary ocular signs were vitreous opacities, beginning from the third or fourth decade, accompanied by retinal vasculitis, hemorrhages, and widespread pinpoint deposits in the peripheral retina. Two patients underwent vitrectomy with marked improvement of visual acuity postoperatively. Vitreous and serum samples for VEGF were analyzed with an enzyme-linked immunosorbent assay (ELISA). Forty-eight healthy adult volunteers were enrolled as a control group for the analysis of serum VEGF. Eight subjects who underwent vitrectomy for a macular epiretinal membrane or macular hole were enrolled as control for the analysis of vitreous VEGF. Both serum and vitreous VEGF levels of patients were raised compared to that of controls. Venous blood was collected from family members and the genomic DNA was extracted. All exons and exon-intron boundaries of the TTR gene were sequenced. A previously-described pathogenic transversion in exon 2 (c.G106C, p.Ala36Pro) was identified. Within this family eight individuals were confirmed as affected. In conclusion, a Chinese family with TTR Ala36Pro associated FTA is characterized by early ocular involvement. Widespread pinpoint lesions indicate RPE lesions caused by TTR deposition. FTA is associated with increased VEGF levels, both in serum and vitreous.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438977     DOI: 10.1016/j.exer.2013.02.005

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  6 in total

1.  Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.

Authors:  Eve Piekarski; Renata Chequer; Vincent Algalarrondo; Ludivine Eliahou; Besma Mahida; Jonathan Vigne; David Adams; Michel S Slama; Dominique Le Guludec; Francois Rouzet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-06       Impact factor: 9.236

Review 2.  Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives.

Authors:  João Heitor Marques; João Coelho; Maria João Menéres; João Melo Beirão
Journal:  Clin Ophthalmol       Date:  2022-07-09

3.  Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion.

Authors:  Lasse Jørgensen Cehofski; Anders Kruse; Alexander Nørgård Alsing; Jonas Ellegaard Nielsen; Shona Pedersen; Svend Kirkeby; Bent Honoré; Henrik Vorum
Journal:  Mol Vis       Date:  2018-11-26       Impact factor: 2.367

4.  Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study.

Authors:  Kang Du; Fan Li; Hui Wang; Yuanfeng Miao; He Lv; Wei Zhang; Zhaoxia Wang; Yun Yuan; Lingchao Meng
Journal:  Ann Clin Transl Neurol       Date:  2021-03-19       Impact factor: 4.511

5.  Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China.

Authors:  Xinyue He; Zhuang Tian; Hongzhi Guan; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2022-09-02       Impact factor: 4.303

6.  Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation: a case report.

Authors:  Arnaldo Dias-Santos; Joana Ferreira; João Paulo Cunha
Journal:  J Med Case Rep       Date:  2014-10-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.